{"id":"NCT01201798","sponsor":"Alcon Research","briefTitle":"Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis","officialTitle":"A Phase 3 Multicenter, Randomized, Double-Masked Study of the Safety and Efficacy of Difluprednate 0.05% Ophthalmic Emulsion Compared to Prednisolone Acetate 1% Ophthalmic Suspension in the Treatment of Endogenous Anterior Uveitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10","primaryCompletion":"2011-08","completion":"2011-08","firstPosted":"2010-09-15","resultsPosted":"2012-11-15","lastUpdate":"2012-11-15"},"enrollment":111,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Endogenous Anterior Uveitis"],"interventions":[{"type":"DRUG","name":"Difluprednate 0.05% ophthalmic emulsion","otherNames":["Durezol"]},{"type":"DRUG","name":"Prednisolone acetate 1.0% ophthalmic suspension","otherNames":["Pred Forte"]}],"arms":[{"label":"Durezol","type":"EXPERIMENTAL"},{"label":"Pred Forte","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to demonstrate that difluprednate 0.05% (Durezol) dosed 4 times daily is noninferior to prednisolone 1% (Pred Forte) dosed 8 times daily for the treatment of endogenous anterior uveitis.","primaryOutcome":{"measure":"Change From Baseline (Day 0) in Anterior Chamber Cell Grade at Day 14","timeFrame":"Baseline (Day 0), Day 14","effectByArm":[{"arm":"Durezol","deltaMin":2.6,"sd":0.68},{"arm":"Pred Forte","deltaMin":2.6,"sd":0.68}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["24677110"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":56},"commonTop":["Intraocular Pressure Increased","Headache","Iridocyclitis","Punctate keratitis"]}}